This virtual public workshop will provide a venue to examine and highlight bottlenecks to innovation in drug research and development (R&D) for prevalent chronic diseases. Workshop participants will consider cross-cutting challenges to encouraging early-stage R&D in prevalent chronic diseases, and discuss considerations and/or strategies for spurring innovation in drug R&D for prevalent chronic diseases.
Half of all Americans live with at least one chronic disease, such as heart disease, cancer, stroke, or diabetes. These and other chronic diseases are the leading cause of death and disability in the United States and are a leading driver of health care costs1.Yet investment in the leading causes of death and disability, other than cancer, has not reflected this increase. Published data from BIO has shown that venture investment for drug development in areas such as psychiatric disorders, cardiovascular, diabetes, and respiratory diseases has declined over the last decade relative to the prevalence and health care cost of these diseases2. The recent outbreak of Coronavirus Disease 2019 (COVID-19) may further exacerbate the health disparities associated with highly prevalent chronic diseases. A case series on hospitalized COVID-19 patients in the New York City area showed that the most common comorbidities were hypertension, obesity, and diabetes3.
A planning committee of the National Academies of Sciences, Engineering, and Medicine, will organize and conduct a public workshop to examine and highlight the bottlenecks to innovation in drug research and development (R&D) for prevalent chronic diseases and consider challenges and opportunities for spurring drug R&D in this space.
The public workshop will feature invited presentations and discussions to:
- Discuss the unique cross-cutting challenges for spurring early stage innovation in drug R&D for prevalent chronic diseases (e.g. do we have promising targets?)
- Consider whether cultural and financial incentives are in alignment for spurring the type of product development that will address unmet need when it comes to prevalent chronic diseases (e.g., do we have the right business models in place?)
- Consider lessons learned from other disease areas (e.g., rare diseases) and/or use cases that could have cross-cutting applications for prevalent chronic diseases.
- Discuss considerations and/or strategies to spur drug R&D innovation for prevalent chronic diseases (i.e., determine whether there are promising avenues forward that merit additional time/effort/funding/attention).
The planning committee will organize the workshop, develop the agenda, select and invite speakers and discussants, and moderate or identify moderators for the discussions. A proceedings of the presentations and discussions at the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines.
1. National Center for Chronic Disease Prevention and Promotion (https://www.cdc.gov/chronicdisease/index.htm)
2. Thomas and Wessel, 2018 (https://www.bio.org/sites/default/files/legacy/bioorg/docs/BIO_HPCP_Series-Pain_Addiction_2018-02-08.pdf)
3. Richardson et al, JAMA, 2020 (https://jamanetwork.com/journals/jama/fullarticle/2765184)